Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PTO user fee retention for patent review included in Coble bill (HR 400) passed by subcommittee.

Executive Summary

PTO USER FEE RETENTION LEGISLATION INCORPORATED INTO OMNIBUS patent legislation at a Mar. 5 mark-up of the House Judiciary/Intellectual Property Subcommittee. Subcommittee Chairman Coble's (R-N.C.) "Patent System Improvement Act" (HR 400) now includes a previously separate Coble measure (HR 673) permitting the Patent & Trademark Office to use all of its user fees on patent and trademark reviews. President Clinton's FY 1998 budget proposal would divert $92 mil. in PTO user fees to other government programs, up from $54 mil. in FY 1997 ("The Pink Sheet" March 3, T&G-4).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel